Optibrium’s StarDrop now powered by OpenEye Scientific’s cheminformatics toolkits

Optibrium™ and OpenEye Scientific (OpenEye), leading providers of software and services for drug discovery, today announced that StarDrop™, Optibrium’s software for small molecule design, optimization and data analysis, is now powered by OpenEye Scientific’s cheminformatics toolkits. These industry-leading cheminformatics libraries offer a robust and performance-orientated foundation, that ensures StarDrop will further advance its position as a leading computational software suite and meet the demands posed by future drug discovery projects.

Optibrium’s StarDrop now powered by OpenEye Scientific’s cheminformatics toolkits
Matt Segall, CEO, Optibrium

Optibrium’s lead product, StarDrop, is a comprehensive suite of integrated software deployed by many of the world’s leading pharmaceutical and biotech companies to support their drug discovery programs. StarDrop’s seamless integration of the industry-leading libraries and toolkits developed by OpenEye Scientific, including OEChem, OEDepict and OMEGA, enables accelerated development of Optibrium’s in silico drug discovery technologies and artificial intelligence services.

OpenEye Scientific is an industry leader in the field of cheminformatics software for drug discovery, providing high-performance and robust libraries with a developer-friendly Application Programming Interface, supporting the development of highly customizable software solutions and workflows. The company directly supports pharmaceutical and biotechnology companies as well as making its cheminformatics platform available to software companies, such as Optibrium, enabling high-performance cheminformatics software solutions.

It’s always exciting when we get the opportunity to empower great people with the same foundational software platform that has allowed us to grow and develop for the last twenty years. Optibrium has always had a fantastic product in StarDrop, and it’s an honour to be a part of what they offer to the pharmaceutical industry.”

Dr. Anthony Nicholls, OpenEye Scientific’s CEO

We continue to invest in cutting-edge research to deliver high-quality science and new functionality that is accessible within StarDrop’s intuitive user interface, to the benefit of our global user base. We highly value this collaboration with OpenEye Scientific, a company that shares our commitment to creating best-in-class technologies designed for reliability and performance.”

Dr Matthew Segall, Optibrium’s CEO

The companies continue to work closely together to leverage future opportunities to advance their respective platforms.

Source:

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Optibrium Ltd.. (2020, May 13). Optibrium’s StarDrop now powered by OpenEye Scientific’s cheminformatics toolkits. News-Medical. Retrieved on July 07, 2020 from https://www.news-medical.net/news/20200513/Optibriume28099s-StarDrop-now-powered-by-OpenEye-Scientifice28099s-cheminformatics-toolkits.aspx.

  • MLA

    Optibrium Ltd.. "Optibrium’s StarDrop now powered by OpenEye Scientific’s cheminformatics toolkits". News-Medical. 07 July 2020. <https://www.news-medical.net/news/20200513/Optibriume28099s-StarDrop-now-powered-by-OpenEye-Scientifice28099s-cheminformatics-toolkits.aspx>.

  • Chicago

    Optibrium Ltd.. "Optibrium’s StarDrop now powered by OpenEye Scientific’s cheminformatics toolkits". News-Medical. https://www.news-medical.net/news/20200513/Optibriume28099s-StarDrop-now-powered-by-OpenEye-Scientifice28099s-cheminformatics-toolkits.aspx. (accessed July 07, 2020).

  • Harvard

    Optibrium Ltd.. 2020. Optibrium’s StarDrop now powered by OpenEye Scientific’s cheminformatics toolkits. News-Medical, viewed 07 July 2020, https://www.news-medical.net/news/20200513/Optibriume28099s-StarDrop-now-powered-by-OpenEye-Scientifice28099s-cheminformatics-toolkits.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.